Safe and Efficient CRISPR Genome Editing of Primary Human T Cells Using a Droplet‐Based Cell Mechanoporation Platform

Why It Matters

Mechanoporation offers a safer, more scalable alternative to electroporation, accelerating the production of next‑generation T‑cell immunotherapies while reducing cellular stress and manufacturing bottlenecks.

Key Takeaways

• 98% dextran delivery, >90% viability at high cell density
• mRNA transfection reaches ~99% efficiency for CAR expression
• CRISPR RNP editing up to 2.35× electroporation efficiency
• Supports single and multiplex knockouts without compromising phenotype
• Scalable microfluidic platform suitable for clinical manufacturing

Pulse Analysis

Adoptive T‑cell therapies have reshaped oncology, but their commercial rollout remains hampered by intracellular delivery bottlenecks. Traditional electroporation, while effective, inflicts membrane damage, triggers stress pathways, and struggles to maintain high viability at manufacturing scales. The droplet‑based mechanoporation system sidesteps these issues by applying controlled mechanical forces within microfluidic droplets, creating transient pores that permit large biomolecules to enter cells without compromising membrane integrity. This physics‑driven approach aligns with Good Manufacturing Practice (GMP) requirements, offering a reproducible, closed‑system solution for cell processing facilities.

Performance data underscore the platform’s competitive edge. Near‑quantitative delivery of 2000 kDa dextran demonstrates the ability to transport sizable cargos, while mRNA transfection rates approach 99%, enabling rapid, tunable expression of chimeric antigen receptors. When delivering CRISPR‑Cas9 ribonucleoproteins, editing efficiencies surpass electroporation by up to 2.35‑fold, and multiplex knockouts of TRAC and PDCD‑1 are achieved without detectable loss of viability or phenotypic drift. Importantly, longitudinal monitoring shows sustained proliferation and genome stability, addressing safety concerns that have limited broader adoption of gene‑edited T‑cell products.

For the biotech industry, this technology could redefine cost structures and timelines for cell‑based therapeutics. Its scalability—supporting high‑density cell suspensions—and compatibility with existing bioprocessing pipelines reduce capital expenditures and labor intensity. Moreover, the gentle nature of mechanoporation may ease regulatory scrutiny by minimizing off‑target cellular stress signatures. As the field moves toward all‑ogeneic, off‑the‑shelf CAR‑T and multiplexed gene‑edited products, droplet mechanoporation offers a versatile, future‑proof platform that bridges the gap between laboratory innovation and commercial reality.